| dc.description.abstract | Natural infection and vaccination are the two ways in which
immunity to SARS-CoV-2 can be acquired.
Regarding adaptive immunity to SARS-CoV-2, both T cells,
and B cell producing neutralizing antibodies (nAbs)
contribute some degree of clinical protection.
The important role of neutralizing antibodies in protection
of SARS-CoV-2 has been demonstrated by the results of
passive transfer of nAbs to non-RBD epitopes on the spike
(S) protein that was able to prevent severe SARS-CoV-2
infection in animal models.
Regeneron has reported similar data in humans (passive
vaccination).
Convalescent plasma transformation has also shown an
ability to dramatically improve clinical symptoms.
Pizer/BioNTech (BNT162b2), is a lipid nanoparticle formulated nucleoside-modified mRNA that encodes the
viral spike glycoprotein of SARS-CoV-2. | en_US |
